umbralisib
FDA Withdraws Umbralisib Due to Elevated Mortality Risk
The FDA announced that it has withdrawn approval for umbralisib (Ukoniq, TG Therapeutics), based on an updated ...
JUNE 3, 2022
FDA Grants Accelerated Approval to Ukoniq for Previously Treated MZL and FL
The FDA approved umbralisib (Ukoniq, TG Therapeutics) for adults with relapsed or refractory marginal zone lymphoma ...
FEBRUARY 17, 2021
Load more